Abstracts Archive - Page 999 of 2425 - ACR Meeting Abstracts

Abstract Number: 670 • 2019 ACR/ARP Annual Meeting
Association Between Ambient Air Pollutant Exposures and Childhood-Onset Systemic Lupus Erythematosus: A 12-Year Population-Based Cohort Study in Taiwan
Yenju Shih¹ and Chang-Ching Wei ², ¹Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Taichung city, Taiwan (Republic of China), ²Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Children Hospital, China Medical University Hospital, Taichung, Taiwan, Taichung city, Taiwan (Republic of China)
Background/Purpose: Air pollutants exposure has been linked to inducing oxidative stress, pulmonary and systemic inflammation. We hypothesized that long-term exposure to air pollution would be…
Abstract Number: 671 • 2019 ACR/ARP Annual Meeting
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
John G Hanly¹, Qiuju Li ², Li Su ³, Murray Urowitz ⁴, Caroline Gordon ⁵, Sang-Cheol Bae ⁶, Juanita Romero-Diaz ⁷, Jorge Sanchez-Guerrero ⁸, Sasha Bernatsky ⁹, Ann E Clarke ¹⁰, Daniel J Wallace ¹¹, David A Isenberg ¹², Anisur Rahman ¹³, Joan Merrill ¹⁴, Paul Fortin ¹⁵, Dafna Gladman ¹⁶, Ian Bruce ¹⁷, Michelle Petri ¹⁸, Ellen M Ginzler ¹⁹, MA Dooley ²⁰, Kristjan Steinsson ²¹, Rosalind Ramsey-Goldman ²², Asad A Zoma ²³, Susan Manzi ²⁴, Ola Nived ²⁵, Andreas Jönsen ²⁵, Munther A Khamashta ²⁶, Graciela Alarcón ²⁷, Elisabet Svenungsson ²⁸, Ronald F Van Vollenhoven ²⁹, Cynthia Aranow ³⁰, Meggan Mackay ³¹, Guillermo Ruiz-Irastorza ³², Manuel Ramos-Casals ³³, S Sam Lim ³⁴, Murat Inanc ³⁵, Kenneth C Kalunian ³⁶, Soren Jacobsen ³⁷, Christine Peschken ³⁸, Diane Kamen ³⁹, Anca Askanase ⁴⁰, Chris Theriault ¹ and Vernon Farewell ², ¹Dalhousie University, Halifax, NS, Canada, ²University of Cambridge, Cambridge, United Kingdom, ³Universidy of Cambridge, Cambridge, United Kingdom, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁸Toronto Western Hospital, Toronto, ON, Canada, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Cedars-Sinai Medical Centre, Beverly Hills, CA, ¹²Centre for Rheumatology, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, ¹⁵Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁶Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ¹⁷University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹State University of New York Downstate Medical Center, Brooklyn, NY, ²⁰UnC Kidney Centre, Chapel Hill, NC, ²¹Landspitali, University Hospital, Reykjavik, Iceland, ²²Northwestern University, Chicago, IL, ²³University of Glasgow, East Kilbride, United Kingdom, ²⁴Allegheny Health Network, Pittsburg, PA, ²⁵Lund University, Lund, Sweden, ²⁶King's College London School of Medicine, London, United Kingdom, ²⁷University of Alabama at Birmingham, Birmingham, ²⁸Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²⁹Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³⁰Feinstein Institute for Medical Research, Manhasset, NY, ³¹Feinstein Institute for Medical Research, New York, ³²Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Barakaldo, Spain, ³³Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ³⁴Emory University, Atlanta, GA, ³⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁶UC San Diego School of Medicine, LaJolla, CA, ³⁷Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁸University of Manitoba, Winnipeg, Canada, ³⁹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ⁴⁰Columbia University Medical Center, New York, NY
Background/Purpose: Although there is a large body of work on central nervous system (CNS) disease in SLE patients, involvement of the peripheral nervous system (PNS)…
Abstract Number: 672 • 2019 ACR/ARP Annual Meeting
Mouse SLE Studies Do Not Describe Human SLE
Ecem Sevim¹, Linjia Jia ², David Fernandez ³ and Michael Lockshin ⁴, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Mary Kirkland Center for Lupus Research, New York, NY, ⁴Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Although mouse models of systemic lupus erythematosus (SLE) are useful proxies for human illness, they are heterogeneous, and publications about mouse SLE may not…
Abstract Number: 673 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center
Elizabeth Graef¹, Daniel Magliulo ¹, Norris Hollie ¹, Chelsea Marcus ² and Vasileios Kyttaris ³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: While lymphadenopathy and/or lymphadenitis (LAD) is considered a relatively common clinical finding in SLE patients, its clinical significance is poorly understood. Previous studies described…
Abstract Number: 674 • 2019 ACR/ARP Annual Meeting
Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)
Kimberly DeQuattro¹, Laura Trupin ¹, Patricia Katz ¹, Stephanie Rush ¹, Louise Murphy ², Maria Dall'Era ¹ and Jinoos Yazdany ³, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Among rheumatologic conditions, SLE is associated with very high healthcare and out of pocket costs. Little is known about patients’ concerns regarding costs of…
Abstract Number: 675 • 2019 ACR/ARP Annual Meeting
Clinical and Serological Lupus Activity Before and After Developing End Stage Renal Disease
Maria Salgado Guerrero¹, Alejandra Londono Jimenez ², Chrisanna Dobrowolsky ², Shudan Wang ², Wenzhu B. Mowrey ³ and Anna Broder ², ¹Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: SLE disease activity tends to diminish after the development of end stage renal disease (ESRD)1, 2. Nonetheless, some patients continue to show signs of…
Abstract Number: 676 • 2019 ACR/ARP Annual Meeting
Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments
Zahi Touma¹, Benjamin Hoskin ², Christian Atkinson ², David Bell ², Olivia Massey ³, Jennifer Lofland ⁴, Pamela Berry ⁵, Chetan Karyekar ⁶ and Karen Costenbader ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Adelphi Real World, Cheshire, United Kingdom, ³Adelphi Real World, Bollington, United Kingdom, ⁴Janssen Scientific Affairs, LLC, Spring House, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, ⁶Janssen Global Services, LLC, Horsham, PA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous systemic lupus erythematosus (SLE) studies have identified potential clusters of SLE clinical manifestations. To describe the presentation of SLE across different cohorts of patients…
Abstract Number: 677 • 2019 ACR/ARP Annual Meeting
Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery
Mahta Kakvan ¹, Robin Green ², Lesley Ruttan ³, Maria Tartaglia ⁴, Joan Wither ⁵, Moe Zandy ¹, Dennisse Bonilla ¹, May Choi ⁶, Jiandong Su ¹, Marvin Fritzler ⁶, Dorcas Beaton ⁷ and Zahi Touma¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, Toronto, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a common neuropsychological manifestation of Systemic Lupus Erythematosus (SLE) with a prevalence of 38% [95% confidence interval: 33,43%]. Previous studies,…
Abstract Number: 678 • 2019 ACR/ARP Annual Meeting
Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease
Martin Aringer¹, Ralph Brinks ², Karen Costenbader ³, David Daikh ⁴, Dimitrios Boumpas ⁵, David Jayne ⁶, Diane Kamen ⁷, Marta Mosca ⁸, Rosalind Ramsey-Goldman ⁹, Josef Smolen ¹⁰, David Wofsy ¹¹, Betty Diamond ¹², Søren Jacobsen ¹³, W Joseph McCune ¹⁴, Guillermo Ruiz-Irastorza ¹⁵, Matthias Schneider ¹⁶, Murray Urowitz ¹⁷, George Bertsias ¹⁸, Bimba Hoyer ¹⁹, Nicolai Leuchten ²⁰, Chiara Tani ²¹, Sara K. Tedeschi ²², Zahi Touma ¹⁷, Branimir Anic ²³, Florence Assan ²⁴, Daniel TM Chan ²⁵, Ann E Clarke ²⁶, Mary Crow ²⁷, László Czirják ²⁸, Andrea Doria ²⁹, Winfried Graninger ³⁰, Bernadette Halda-Kiss ³¹, Sarfaraz Hasni ³², Peter Izmirly ³³, Michelle Jung ²⁶, Gabor Kumanovics ³¹, Xavier Mariette ³⁴, Ivan Padjen ²³, Jose Maria Pego-Reigosa ³⁵, Juanita Romero-Diaz ³⁶, Iñigo Rua Figueroa ³⁷, Raphaèle Seror ²⁴, Georg Stummvoll ¹⁰, Yoshiya Tanaka ³⁸, Maria Tektonidou ³⁹, Carlos Vasconcelos ⁴⁰, Edward Vital ⁴¹, Daniel Wallace ⁴², Sule Yavuz ⁴³ Raymond Naden ⁴⁴, Thomas Dörner ⁴⁵ and Sindhu R. Johnson ⁴⁶, ¹Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, ²Department of Rheumatology and Hiller Research Unit of Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of California at San Francisco and VA Medical Center, San Francisco, CA, ⁵University of Athens, Athens, Greece, ⁶Vasculitis and Lupus Clinic, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom, ⁷Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁸Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁹Northwestern University, Chicago, IL, ¹⁰Medical University of Vienna, Vienna, Austria, ¹¹UCSF, San Francisco, ¹²Feinstein Institutes for Medical Research, Manhasset, ¹³Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, ¹⁶Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ¹⁷University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁸University of Crete, Rheumatology, Clinical Immunology and Allergy Unit, Heraklion, Greece, ¹⁹University of Schleswig-Holstein at Kiel, and Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Kiel, Germany, ²⁰University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²¹Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ²²Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²³UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, ²⁴Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²⁵University of Hong Kong, Hong Kong, Hong Kong, ²⁶University of Calgary, Calgary, AB, Canada, ²⁷Hospital for Special Surgery, New York, NY, ²⁸Dept. of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, ²⁹University and Azienda Ospedaliera of Padova, Padova, Italy, ³⁰Medical University of Graz, Graz, Austria, ³¹University of Pécs, Pécs, Hungary, ³²NIAMS, National Institutes of Health, Bethesda, MD, ³³NYU School of Medicine, New York, ³⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ³⁵Complexo Hospitalario Universitario, Vigo, Spain, ³⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ³⁷Hospital Doctor Negrin, Las Palmas, ³⁸University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³⁹First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁴⁰University of Porto, UMIB Abel Salazar Biomedical Sciences Institute, Porto, Portugal, ⁴¹University of Leeds, Leeds, United Kingdom, ⁴²Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁴³Uppsala University, Istanbul, Turkey, ⁴⁴McMaster University, Hamilton, ON, Canada, ⁴⁵Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴⁶Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada
Background/Purpose: The EULAR/ACR 2019 Classification Criteria for SLE have been validated in an international cohort of 696 SLE patients and 574 non-SLE patients with a…
Abstract Number: 679 • 2019 ACR/ARP Annual Meeting
Longitudinal Changes in Manifestations of SLE
Amanda Eudy¹, Jennifer Rogers ¹, Raeann Whitney ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, David Pisetsky ², Rebecca Sadun ¹, Kai Sun ¹ and Megan Clowse ¹, ¹Duke University, Durham, ²Duke University, Durham VAMC, Durham
Background/Purpose: Our group has developed a conceptual model to categorize SLE manifestations into two dimensions termed Type 1 and Type 2. Type 1 SLE consists…
Abstract Number: 680 • 2019 ACR/ARP Annual Meeting
Patients Who Do Not Fulfill the 2018 EULAR/ACR Criteria for Systemic Lupus Erythematosus Accrue Less Damage: Data from a Multicenter, Multiethnic US Cohort
Manuel Ugarte-Gil¹, Guillermo Pons-Estel ², Luis Vilá ³, Russell Griffin ⁴ and Graciela Alarcón ⁵, ¹Universidad Científica del Sur, Lima, Peru, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: The 2018 EULAR/ACR Criteria for the classification of patients with systemic lupus erythematosus (SLE) were proposed in order to improve the sensitivity and specificity…
Abstract Number: 681 • 2019 ACR/ARP Annual Meeting
Evaluation of the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and Patient Reported Outcome (PRO) in a Primarily Mestizo Population
Manuel Ugarte-Gil¹, Rocío-V. Gamboa-Cárdenas ², Cristina Reátegui-Sokolova ³, Victor Pimentel-Quiroz ⁴, Paola Zeña-Huancas ², Mariela Medina ², Claudia Elera-Fitzcarrald ¹, Samira García ³, Luciana Gil ², Erika Noriega ², Cesar Pastor-Asurza ³, Zoila Rodríguez-Bellido ², Joan Merrill ⁵, Anca Askanase ⁶, Graciela Alarcón ⁷ and Risto Perich-Campos ², ¹Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Columbia University, New York, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: There are several instruments to measure disease activity in patients with systemic lupus erythematosus (SLE); however, none of them are able to capture all…
Abstract Number: 682 • 2019 ACR/ARP Annual Meeting
Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population
Manuel Ugarte-Gil¹, Rocío-V. Gamboa-Cárdenas ², Victor Pimentel-Quiroz ³, Cristina Reátegui-Sokolova ⁴, Paola Zeña-Huancas ², Mariela Medina ², Claudia Elera-Fitzcarrald ¹, Luciana Gil ², Samira García ⁴, Francisco Zevallos ⁴, Cesar Pastor-Asurza ⁴, Zoila Rodríguez-Bellido ², Anca Askanase ⁵, Joan Merrill ⁶, Graciela Alarcón ⁷ and Risto Perich-Campos ², ¹Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ³Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Columbia University, New York, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: Disease activity in systemic lupus erythematosus (SLE) is understood differently by patients and physicians; furthermore, there are no reliable measures for patients to assess…
Abstract Number: 683 • 2019 ACR/ARP Annual Meeting
Biologic Differences Between Type 1 and 2 Lupus
Megan Clowse¹, Jennifer Rogers ¹, Amanda Eudy ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, Rebecca Sadun ¹, Kai Sun ¹, Micah McClain ², Ephraim Tsalik ³, Chris Woods ², David Pisetsky ⁴, Prathyusha Bachali ⁵, Amrie Grammer ⁶, Michelle Catalina ⁵ and Peter Lipsky ⁷, ¹Duke University, Durham, ²Duke University & Duke Center for Applied Genomics & Precision Medicine, Durham, ³Duke University, Duke Center for Applied Genomics & Precision Medicine, Durham VA, Durham, ⁴Duke University, Durham VAMC, Durham, ⁵AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ⁶AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, ⁷AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: The manifestations of systemic lupus erythematosus (SLE) can be divided into categories according to a recently proposed model: a category of classic active autoimmune-driven…
Abstract Number: 684 • 2019 ACR/ARP Annual Meeting
Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis
Min Jung Kim¹, Hajeong Lee ¹, Yeong-Wook Song ¹ and Eun Bong Lee ², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul
Background/Purpose: Renal flares are common during treatment of biopsy-proven lupus nephritis (LN). However, it is unknown whether biopsy should be repeated in the event of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].